These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 12610240)

  • 1. Bridging the gap: a hybrid model to link efficacy and effectiveness research in substance abuse treatment.
    Carroll KM; Rounsaville BJ
    Psychiatr Serv; 2003 Mar; 54(3):333-9. PubMed ID: 12610240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research.
    Wells KB
    Am J Psychiatry; 1999 Jan; 156(1):5-10. PubMed ID: 9892291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telemedicine for the Medicare population: pediatric, obstetric, and clinician-indirect home interventions.
    Hersh WR; Wallace JA; Patterson PK; Shapiro SE; Kraemer DF; Eilers GM; Chan BK; Greenlick MR; Helfand M
    Evid Rep Technol Assess (Summ); 2001 Aug; (24 Suppl):1-32. PubMed ID: 11569328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Organizational and client determinants of cost in outpatient substance abuse treatment.
    Beaston-Blaakman A; Shepard D; Horgan C; Ritter G
    J Ment Health Policy Econ; 2007 Mar; 10(1):3-13. PubMed ID: 17417043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and methodological considerations of an effectiveness trial of a computer-assisted intervention: an example from the NIDA Clinical Trials Network.
    Campbell AN; Nunes EV; Miele GM; Matthews A; Polsky D; Ghitza UE; Turrigiano E; Bailey GL; VanVeldhuisen P; Chapdelaine R; Froias A; Stitzer ML; Carroll KM; Winhusen T; Clingerman S; Perez L; McClure E; Goldman B; Crowell AR
    Contemp Clin Trials; 2012 Mar; 33(2):386-95. PubMed ID: 22085803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engaging stakeholders in review and recommendations for models of outcome monitoring for substance abuse treatment.
    Rush B; Martin G; Corea L; Rotondi NK
    Subst Use Misuse; 2012 Oct; 47(12):1293-302. PubMed ID: 22780842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moving evidence-based drug abuse prevention programs from basic science to practice: "bridging the efficacy-effectiveness interface".
    August GJ; Winters KC; Realmuto GM; Tarter R; Perry C; Hektner JM
    Subst Use Misuse; 2004; 39(10-12):2017-53. PubMed ID: 15587956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening and brief intervention for alcohol and other abuse.
    Harris SK; Louis-Jacques J; Knight JR
    Adolesc Med State Art Rev; 2014 Apr; 25(1):126-56. PubMed ID: 25022191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of family-based substance abuse treatment.
    Morgan TB; Crane DR
    J Marital Fam Ther; 2010 Oct; 36(4):486-98. PubMed ID: 21039660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Manual-guided cognitive-behavioral therapy training: a promising method for disseminating empirically supported substance abuse treatments to the practice community.
    Morgenstern J; Morgan TJ; McCrady BS; Keller DS; Carroll KM
    Psychol Addict Behav; 2001 Jun; 15(2):83-8. PubMed ID: 11419234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of treatment benefits: clinical endpoints relevant to patients.
    Prescrire Int; 2008 Dec; 17(98):260. PubMed ID: 19425279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A vision of the next generation of behavioral therapies research in the addictions.
    Carroll KM; Rounsaville BJ
    Addiction; 2007 Jun; 102(6):850-62; discussion 863-9. PubMed ID: 17523974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of drug abuse treatment: relevant issues and alternative longitudinal modeling approaches.
    Hser YI; Anglin MD
    NIDA Res Monogr; 1991; 113():67-93. PubMed ID: 1762644
    [No Abstract]   [Full Text] [Related]  

  • 14. Critical issues in the development of culturally relevant substance abuse treatments for specific minority groups.
    Gonzàlez Castro F; Garfinkle J
    Alcohol Clin Exp Res; 2003 Aug; 27(8):1381-8. PubMed ID: 12966344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MET meets the real world: design issues and clinical strategies in the Clinical Trials Network.
    Carroll KM; Farentinos C; Ball SA; Crits-Christoph P; Libby B; Morgenstern J; Obert JL; Polcin D; Woody GE
    J Subst Abuse Treat; 2002 Sep; 23(2):73-80. PubMed ID: 12220604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ethical pitfalls in neonatal comparative effectiveness trials.
    Modi N
    Neonatology; 2014; 105(4):350-1. PubMed ID: 24931328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy.
    Tunis SR; Stryer DB; Clancy CM
    JAMA; 2003 Sep; 290(12):1624-32. PubMed ID: 14506122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cost-effectiveness model for evaluating health care programs: application to drug abuse treatment.
    Goldschmidt PG
    Inquiry; 1976 Mar; 13(1):29-47. PubMed ID: 130347
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy vs effectiveness trial results of an indicated "model" substance abuse program: implications for public health.
    Hallfors D; Cho H; Sanchez V; Khatapoush S; Kim HM; Bauer D
    Am J Public Health; 2006 Dec; 96(12):2254-9. PubMed ID: 16809591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.